Clinical trials
Treatment clinical trials
Below are recruiting treatment clinical trials, each written for real people, not researchers. We’re tracking 8,307 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT05909709RecruitingPhase 1
Tested injections for chronic facet-related back pain
This Phase 1 study tests the safety of an injection called Alocyte in adults with long-lasting back pain coming from the facet joints. If you qualify, you may be followed closely to check side effects and how you respond over multiple visits.
North Miami, FloridaAges 18 years+ - NCT05903027Recruiting
Testing gepant migraine treatment for better side effects
This trial studies how well a “gepant” medicine works for different types of migraine and how tolerable it is. It may help if you have frequent migraines and you can keep a headache diary as the study asks.
FlorenceAges 18 years+ - NCT05880212Recruiting
STOPS low back and leg pain approach for Bangladesh
This trial tests a specific physiotherapy program (“STOPS approach”) for people with long-lasting low back pain or leg pain from the back. It aims to see if the structured treatment, delivered by trained physiotherapists, improves pain and function over about 10 weeks.
Dhaka, UttaraAges 18–65 - NCT05905705Recruiting
ECT plus a sleep monitor for treatment-resistant depression
This study looks at how electroconvulsive therapy (ECT) affects brain activity and sleep patterns in people with difficult-to-treat depression. It uses a wearable sleep monitor (the Dreem device) to record sleep while you receive ECT.
St Louis, MissouriAges 21–65 - NCT05901818RecruitingPhase 1
Testing a patient’s own stem-cell treatment for Parkinson’s
This Phase 1 study tests whether an “autologous” (from your own body) iNSC-DAP stem-cell treatment is safe and may help symptoms in Parkinson’s disease. It is designed mainly to check safety, while also watching for signs of improvement.
Beijing, Beijing MunicipalityAges 30–85 - NCT05880914Recruiting
Personalized treatment study for bone disease in kidney failure
This trial looks at a personalized approach to diagnosing and treating bone problems caused by long-term kidney disease. It may help by matching treatment plans to the type of bone turnover found in your tests or biopsy.
St Louis, MissouriAges 18 years+ - NCT05891821RecruitingPhase 2
Balstilimab for relapsed lymphoma after standard treatments failed
This phase 2 study tests balstilimab to see if it can be safe and effective for certain lymphomas that came back or didn’t respond to standard treatment. If you qualify, you’ll be checked closely for side effects and how well your lymphoma responds.
YerevanAges 18 years+ - NCT05890677Recruiting
Surgery versus conservative care for chronic breast-related arm swelling
This trial compares microsurgery to standard conservative therapy for long-lasting arm swelling caused by prior breast cancer. It may help people who still have swelling despite months of decongestive treatment by improving quality of life.
New Haven, ConnecticutAges 18 years+ - NCT05905926Enrolling by invitationPhase 3
Tenapanor safety study for teens with constipation-predominant IBS
This trial checks the safety of tenapanor in children and teens (ages 6 to under 18) with IBS-C. It is only for people who finished a previous related study and agreed to continue follow-up.
Foley, AlabamaAges 6–18 - NCT05901285RecruitingPhase 1
Vaccine injected into tumors plus immunotherapy for advanced cancers
This Phase 1 trial tests a cancer vaccine (VAX014) injected directly into a tumor, given alone at first and then with an immune checkpoint medicine (nivolumab or pembrolizumab). It aims to see how well this approach is tolerated and may help shrink advanced solid tumors after other treatments stopped working.
Tucson, ArizonaAges 18 years+ - NCT05896397Recruiting
Collecting European data for Cook aortic medical devices
This study collects information from routine care about patients who receive a Cook CMD. It may help improve how these devices are used and tracked over time by using medical record data.
Aarhus, DenmarkAges Any age - NCT05741359RecruitingPhase 1
Study of BRL-201 for hard-to-treat aggressive B-cell lymphoma
This Phase 1 study tests BRL-201 (an anti-CD19 treatment) for safety and early signs of effectiveness in adults with relapsed or refractory aggressive B-cell non-Hodgkin lymphoma. It may help people whose lymphoma has returned or not responded to prior treatments.
Wuhan, HubeiAges 18 years+ - NCT05868421Recruiting
Veteran coaching with a trusted person to quit smoking
This study tests whether involving a supportive family member or friend can help a veteran use smoking-quit treatment more effectively. If you’ve smoked recently and can name a trusted contact who will join, you may be able to participate.
Minneapolis, MinnesotaAges 18 years+ - NCT05861752Recruiting
Study of sexual risk behaviors and mental health patterns
This case-control study looks at people with specific sexual behavior-related conditions (like certain paraphilias, compulsive sexual behavior, or sex during sleep) to understand factors linked with risk for sexual violence. The goal is to learn what patterns may be involved so better help and prevention strategies can be developed.
Stockholm, Stockholm CountyAges 18 years+ - NCT05850273Recruiting
Study how interferon works in blood cancer patients
This study looks at how a medicine called pegylated interferon affects “myeloproliferative neoplasms” (MPNs), a group of slow-growing blood cancers. You may be included whether your MPN is newly diagnosed or already being treated, mainly to help researchers understand the treatment’s effects.
Villejuif, Île-de-France RegionAges 18 years+ - NCT05865457Recruiting
Testing two eye treatments for dry eye symptoms
This trial compares two different dry-eye eye drops to see which works better and is safe. You may be able to join if you’ve had dry eye for at least 3 months and meet specific eye-test results.
GrazAges 18 years+ - NCT05860465RecruitingPhase 2/Phase 3
Tested blood cancer medicine with hormone therapy for breast cancer
This trial studies SPH4336 given together with standard hormone (endocrine) therapy for breast cancer that has spread or cannot be treated with surgery. It aims to see whether the combination is safer and more effective than hormone therapy alone.
Guangzhou, GuangdongAges 18–75 - NCT05850689RecruitingPhase 3
Lumateperone add-on for major depression that didn’t improve
This study tests whether adding lumateperone to an antidepressant helps adults with major depressive disorder (MDD) who haven’t improved enough after trying at least two different antidepressants. It may help reduce depressive symptoms more than antidepressants alone.
Huntsville, AlabamaAges 18–65 - NCT05865379Recruiting
Tested eye drops for dry eye relief and safety
This trial studies whether BUFY01 eye drops work better than SVS20 for treating dry eye disease. You may be able to join if you have dry eye symptoms for at least 3 months and meet eye exam score and tear-test requirements.
LeuvenAges 18 years+ - NCT05871970RecruitingPhase 2
TARA-002 treatment for lymphatic cysts in children
This Phase 2 trial tests whether an injected medicine called TARA-002 placed inside lymphatic cysts can safely shrink lymphatic malformations in children. It may help especially when the cysts are mainly in the head, neck, or chest area.
Birmingham, AlabamaAges 6 months–18 years - NCT05848284Recruiting
Tricuspid valve replacement to reduce leaking in the heart
This trial tests a new catheter-based procedure that replaces the tricuspid valve to reduce severe valve leaking. It may help people who still have symptoms despite heart medicines, but only if their heart shape and other health details fit the device requirements.
Los Angeles, CaliforniaAges 18 years+ - NCT05868135Recruiting
Online guided therapy for depression and anxiety
This trial tests an internet-based (online) guided psychological program, called e-Meistring, for people with moderate depression plus panic disorder and social anxiety. It aims to see whether the program improves symptoms and is also worth the cost.
BergenAges 18 years+ - NCT05847985Recruiting
Noninvasive brain stimulation for thinking and language issues
This study tests whether a noninvasive brain stimulation treatment can improve sentence understanding in people with Parkinson’s disease–related mild cognitive impairment or mild cognitive impairment from Lewy body disease. It also compares results with healthy volunteers who do not have Lewy body or other memory/brain disorders.
BrnoAges 60–80 - NCT05873634Recruiting
Using health records and testing to study heart failure types
This study combines electronic health record data and detailed heart testing to better understand different heart failure types and what treatments may work best for each. It mainly enrolls people with known heart failure, and also some people without heart failure for comparison.
Sacramento, CaliforniaAges 30 years+
Hear when a new Treatment trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for treatment?
- Yes. Clin2 currently lists 8,307 recruiting treatment studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a treatment trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a treatment trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.